NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
ASX · EBR.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
EBR Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
EBR Systems, Inc.’s next earnings report is currently expected on Mar 3, 2027, with estimated earnings per share of -A$0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow EBR Systems, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
EBR Systems, Inc. is a company focused on creating implantable medical devices that employ wireless technology for tissue stimulation. Their flagship product is the WiSE cardiac resynchronization therapy system, which utilizes a unique wireless method to deliver pacing signals directly inside the left ventricle of the heart. This innovative approach helps overcome the typical challenges linked to traditional pacing leads, including complex insertion, inadvertent nerve activation, displacement, removal procedures, and subsequent adjustments. Established in 2003, the company operates out of Sunnyvale, California.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Aug 12, 2025 | -A$0.04+18.91% vs estimate | A$258.07K-66.69% vs estimate |
|---|
| Q1 2025 | May 13, 2025 | -A$0.04+44.45% vs estimate | A$0.00 |
|---|
| Q4 2024 | Mar 23, 2025 | -A$0.02 | A$0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
A$8.83+A$0.28 (+3.27%)
Anteris Technologies Ltd’s quoted price sits in the lower half of its reported 52-week range, 42.92% below the high.
A$0.91+A$0.03 (+2.84%)
PolyNovo Limited’s quoted price sits in the lower half of its reported 52-week range, 35.13% below the high.
A$1.35+A$0.05 (+3.85%)
Imricor Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
A$0.29-A$0.01 (-3.33%)
SomnoMed Limited’s quoted price sits in the lower half of its reported 52-week range, 69.31% below the high.
A$0.25-A$0.01 (-3.92%)
Saluda Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.11% below the high.
A$0.43+A$0.04 (+10.39%)
Cyclopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 67.05% below the high.
A$0.00-A$0.00 (-11.11%)
ImpediMed Limited’s quoted price sits in the lower half of its reported 52-week range, 90.48% below the high.
